SP-2021A is a human anti-CD33 monoclonal antibody developed by LectinStars Pharmaceuticals Ltd. Pre-clinical experiments have confirmed its ability to activate immune cells in patients with chronic Hepatitis B, prompting the production of antibodies to combat HBsAg. This antibody represents a therapeutic breakthrough with the goal of achieving a cure for chronic Hepatitis B.